Celcuity To Participate in Upcoming Investor Conferences

Core Insights - Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, specifically for multiple solid tumor indications [2] Company Overview - The lead therapeutic candidate of Celcuity is gedatolisib, which is a potent pan-PI3K and mTORC1/2 inhibitor that blocks the PI3K/AKT/mTOR ("PAM") pathway comprehensively [2] - Gedatolisib's mechanism of action and pharmacokinetic properties are distinct from other therapies that target PI3Kα, AKT, or mTORC1 alone or in combination [2] Clinical Trials - A Phase 3 clinical trial, VIKTORIA-1, has completed enrollment, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with HR+/HER2- advanced breast cancer [2] - The company has reported detailed results for the PIK3CA wild-type cohort from the VIKTORIA-1 trial [2] - A second Phase 3 trial, VIKTORIA-2, is ongoing, assessing gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer [2] - A Phase 1/2 clinical trial, CELC-G-201, is also ongoing, evaluating gedatolisib in combination with darolutamide for patients with metastatic castration-resistant prostate cancer [2] Investor Engagement - Brian Sullivan, CEO and Co-founder of Celcuity, will present at various investor conferences and is available for one-on-one meetings [1][3] - Live webcasts of the presentations will be accessible on the company's website, with replays available shortly after the events [1]